BTIG analyst Jeet Mukherjee has reiterated their bullish stance on PVLA stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jeet Mukherjee has given his Buy rating due to a combination of factors, chiefly the strong Phase 3 SELVA topline results for QTORIN rapamycin in microcystic lymphatic malformations, where the primary endpoint improvement exceeded his base-case expectations. The very high proportion of patients achieving meaningful clinical benefit, together with the drug’s favorable tolerability and low systemic exposure, reinforces his conviction that physicians are likely to adopt the therapy if it is approved.
He also notes that all key secondary endpoints were successfully achieved, including a blinded composite measure of lesion characteristics, which supports the robustness and breadth of QTORIN’s clinical effect. The high rate of patients choosing to continue into the open-label extension underscores perceived quality-of-life gains, and, combined with the stock’s strong pre-market reaction, underpins his positive view on PVLA’s risk-reward and justifies his Buy recommendation.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $222.00 price target.